Survey Contents: Biotechnology 2005

1. Executive summary
2. Highlights
3. Industry Overview

3.1 Introduction
3.2 Industry growth
3.2.1 Industry concentric
3.2.2 Industry analysis
3.2.3 R&D expenditure
3.2.4 Strength of the players
3.2.5 Financial flow
3.2.5 NASDAQ biotech index
3.3 The segments
3.3.1 Biopharmaceuticals
3.3.2 Agri-biotechnology
3.3.3 Bioindustry
3.4 Conclusion
3.5 Bibliography

4. Growth Drivers

4.1 Introduction
4.2 The Push behind the Move: Key Growth Drivers
4.2.1 Therapy areas and technology-The expanding horizon
4.2.2 Favorable regulations
4.2.3 Expanding Clientele and market hold
4.2.4 Aging population and life style
4.2.5 Financing abilities
4.2.6 Enhanced Entrepreneurial Culture
4.2.7 Positive growth of related industries
4.2.8 Growth of Contract Research Organizations
4.3 Growth Drivers: Past and the present
4.4 Conclusion
4.4.1 Integrated Biotechnology
4.4.2 Developing and co-development companies
4.4.3 Increased drug targets through genomics
4.5 Bibliography

5. Issues and Challenges

5.1 Introduction
5.2 Major Issues and Challenges
5.2.1 Answer to the ever decreasing fossil fuel
5.2.2 Food safety and security
5.2.3 Human health and medicine
5.2.4 Sustainability of environment
5.2.5 Bioterrorism
5.2.6 Human Genome Project
5.2.7 Cloning and stem cell research - an ever intensifying issue
5.2.8 Genetically Modified Foods - How safe is it
5.2.9 Biosafety and concern of environmentalists
5.2.10 Animal rights issue, violent at times
5.2.11 Biopiracy
5.2.12 Data Exclusivity (DE)
5.2.13 Royalty Stacking
5.3 Tackling the issues and challenges
5.3.1 Equal access of the technology
5.3.2 Establishment of biotechnology associations
5.3.3 Financial Resources
5.3.4 Concerted working of the various research organizations
5.3.5 Balanced and accurate dissemination of information
5.3.6 Solutions to royalty stacking issue
5.4 Conclusion
5.5 Bibliography

6. Technology

6.1 Introduction
6.2 Important technologies
6.2.1 Polymerase chain reaction
6.2.2 Restriction enzymes and ligases
6.2.3 Radioactive tracer
6.2.4 Bioprocess technology
6.2.5 Biotechnology Diagnostics
6.2.6 Monoclonal antibody
6.2.7 Cloning
6.2.8 Genetic therapy
6.2.9 Biosensors
6.2.10 Biocomputer
6.2.11 Bionanotechnology
6.2.12 Microarray
6.2.13 Transgenic Plants
6.2.14 Nutraceuticals
6.2.15 Bioinformatics
6.2.16 Bioremediation
6.2.17 Antisense technology
6.2.18 Proteomics
6.2.19 Stem cell technology
6.3 Technological application for integrating value chain
6.4 Changes in technology and its application during 2005
6.5 Conclusion
6.5.1 Stem cells
6.5.2 Gene therapy
6.5.3 Agriculture
6.5.4 Cloning
6.6 Bibliography

7. Major Markets

7.1 Introduction
7.2 North America
7.2.1 The economy
7.2.2 Biotechnology Industry
7.2.3 Major Biotechnology clusters
7.2.4 Areas of focus
7.3 Europe
7.3.1 The economy
7.3.2 Biotechnology Industry
7.3.3 Major biotechnology clusters in Europe
7.3.4 Areas of focus
7.4 Asia Pacific
7.4.1 The economy
7.4.2 Biotechnology industry
7.4.3 Emerging countries of Asia Pacific
7.4.4 Areas of focus
7.5 Conclusion
7.5 Bibliography

8. Major Players

8.1 Introduction
8.2 Amgen, Inc
8.2.1 Business Profile
8.2.2 Financial and operational performance
8.2.3 Business Strategy: Amgen
8.2.4 Future Outlook
8.3 Genentech
8.3.1 Business Profile
8.3.2 Financial and operational performance
8.3.3 Business Strategy: Genentech
8.3.4 Future Outlook
8.4 Genzyme
8.4.1 Business Profile
8.4.2 Financial and operational performance
8.4.3 Business Strategy: Genzyme
8.4.4 Future Outlook
8.5 Serono SA
8.5.1 Business Profile
8.5.2 Financial and operational performance
8.5.3 Business Strategy: Serono SA
8.5.4 Future Outlook
8.6 Biogen Idec Inc
8.6.1 Business Profile
8.6.2 Financial and operational performance
8.6.3 Business Strategy: Biogen Idec
8.6.4 Future Outlook
8.7 Gilead
8.7.1 Business Profile
8.7.2 Financial and operational performance
8.7.3 Business Strategy: Gilead
8.7.4 Future Outlook
8.8 Chiron Corporation
8.8.1 Business Profile
8.8.2 Financial and operational performance
8.8.3 Business Strategy: Chiron Corporation
8.8.4 Future Outlook
8.9 MedImmune
8.9.1 Business Profile
8.9.2 Financial and operational performance
8.9.3 Business Strategy: MedImmune
8.9.4 Future Outlook
8.10 Invitrogen
8.10.1 Business Profile
8.10.2 Financial and operational performance
8.10.3 Business Strategy: Invitrogen
8.10.4 Future Outlook
8.11 Millennium Pharmaceuticals Inc
8.11.1 Business Profile
8.11.2 Financial and operational performance
8.11.3 Business Strategy: Millennium
8.11.4 Future Outlook
8.12 Monsanto
8.12.1 Business Profile
8.12.2 Financial and operational performance
8.12.3 Business Strategy: Monsanto
8.12.4 Future Outlook
8.13 Syngenta
8.13.1 Business Profile
8.13.2 Financial and operational performance
8.13.3 Future Outlook
8.14 Bibliography

9. Regulations

9.1 Introduction
9.2 Regulatory bodies worldwide
9.2.1 The US
9.2.2 EU
9.2.3 Japan
9.2.4 Australia
9.2.5 India
9.2.6 International organizations involved in regulations
9.3 Laws governing the biotechnology industry
9.3.1The USLaws and Regulations
9.3.2 EU
9.3.3 Japan
9.3.4 India
9.4 Regulatory Changes
9.4.1 UK
9.4.2 India
9.4.3 Croatia
9.5 Conclusion
9.6 Bibliography

10. Mergers and Acquisitions (M&A)

10.1 Introduction
10.2 Drivers for M&A
10.2.1 Product and market extension
10.2.2 Acquire new technology
10.2.3 Operate in new geographies
10.2.4 Wide and cost effective research and development (R&D)
10.2.5 Gaining critical mass
10.2.6 Finance from investors
10.2.7 Implementation of core capability
10.3 Trends of M&A: The way things are happening
10.3.1 Major M&A in the last 3 years
10.3.2 The urge to merge: Heating up around the globe
10.3.3 M&A in 2005: Few giants on a buying spree
10.4 M&A of the year 2005
10.4.1 Novartis AG: Chiron
10.5 Conclusions
10.6 Bibliography

11. Critical Success Factors

11.1 Introduction
11.2 Stimulant of Growth: The Critical Success Factors
11.2.1 Government initiatives
11.2.2 Research and Development (R&D)
11.2.3 Entrepreneurial Environment
11.2.4 Mix of companies in value chain; Proportionate distribution
11.2.5 Spin-offs and start-up firms-The incubators
11.2.6 Effective commercialization
11.2.7 Venture Capital and IPO: The source of sustenance
11.2.8 Critical Alliances: Partnering for Progressing
11.3 Critical Success Factors-Past and the present
11.4 Conclusion
11.5 Bibliography

12. Future Outlook